ADAG

Adagene Inc.

• TipRanks·08/17 15:20

  Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Natera (NTRA)

• TipRanks·08/13 11:10

  Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE), Mineralys Therapeutics, Inc. (MLYS) and Adagene (ADAG)

• TipRanks·08/12 11:57

  Adagene Extends Cash Runway and Advances Muzastotug Through Mid-2026 Clinical Milestones

• Seeking Alpha·08/12 11:51

  Adagene ADR Non-GAAP EPS of -$0.20, revenue of $1.62M

• Benzinga·08/12 11:33

  Adagene H1 Adj. EPS $(0.20) Misses $(0.10) Estimate, Sales $1.620M

• TipRanks·07/06 12:27

  Adagene Discloses Preliminary US$127.9 Million Cash Balance as of June 30, 2026

• NASDAQ·06/18 12:41

  Add Up The Pieces: PGJ Could Be Worth $33

• Benzinga·05/21 21:06

  12 Health Care Stocks Moving In Thursday's After-Market Session

• NASDAQ·05/19 21:07

  Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer

• TipRanks·05/02 17:20

  Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Summit Therapeutics (SMMT)

• TipRanks·04/27 10:55

  Analyst Initiates Buy on Muza Developer, Citing Promising MSS CRC Data, Clear Registrational Path, and Broader Expansion Upside Despite Cash Constraints

• TipRanks·04/17 20:53

  Adagene Showcases Promising Muzastotug Triplet Data at AACR 2026 for Liver and Colorectal Cancers

• TipRanks·04/17 20:15

  Adagene presents data from two Phase 1b/2 studies of muzastotug at AACR

• Benzinga·04/17 20:03

  Adagene's Muzastotug Triplet Regimens Show Superior Response Rates In HCC And MSS CRC, Highlighting Improved Anti-CTLA-4 Tumor-Targeting At AACR 2026

• Seeking Alpha·04/16 18:08

  Adagene Looks Attractive With ADG126 And Validating Partnerships